These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24380737)

  • 41. [Variety of symptoms after drug use of gamma-hydroxybutyric acid (GHB)].
    Galldiks N; Kadow I; Bechdolf A; Fink GR; Klosterkötter J; Kuhn J
    Fortschr Neurol Psychiatr; 2011 Jan; 79(1):21-5. PubMed ID: 21154180
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [ADHD and addiction; application of the Belgian guideline with particular reference to comorbid affective disorders].
    Matthys F; Joostens P; Tremmery S; Stes S; Sabbe B
    Tijdschr Psychiatr; 2013; 55(9):715-9. PubMed ID: 24046250
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report.
    Bennett WR; Wilson LG; Roy-Byrne PP
    J Psychoactive Drugs; 2007 Sep; 39(3):293-6. PubMed ID: 18159783
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Liquid ecstasy in general psychiatry: a case series].
    Freudenmann RW; Baumgarten E; Hawlik AE; Gahr M; Schönfeldt-Lecuona CJ
    Fortschr Neurol Psychiatr; 2013 Feb; 81(2):88-94. PubMed ID: 23412960
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Individual differences in GHB consumption in a new voluntary GHB self-administration model in outbred rats.
    Wolf CJH; Spoelder M; Beurmanjer H; Bulthuis R; Schellekens AFA; Homberg JR
    Psychopharmacology (Berl); 2024 Mar; 241(3):613-625. PubMed ID: 38334790
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Forensic and medical legal issues in addiction psychiatry.
    Gendel MH
    Psychiatr Clin North Am; 2004 Dec; 27(4):611-26. PubMed ID: 15550283
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Within-patient variability in clinical presentation of gamma-hydroxybutyrate withdrawal: a case report.
    Glasper A; McDonough M; Bearn J
    Eur Addict Res; 2005; 11(3):152-4. PubMed ID: 15990433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Gamma-hydroxy butyric acid: neurotransmitter, sedative and party drug].
    Meyer S; Kleinschmidt S; Gottschling S; Gortner L; Strittmatter M
    Wien Med Wochenschr; 2005 Jul; 155(13-14):315-22. PubMed ID: 16092038
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk assessment of GBL as a substitute for the illicit drug GHB in the Netherlands. A comparison of the risks of GBL versus GHB.
    van Amsterdam J; Brunt T; Pennings E; van den Brink W
    Regul Toxicol Pharmacol; 2014 Nov; 70(2):507-13. PubMed ID: 25204614
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Case Presentations from the Addiction Academy.
    Laes JR; Wiegand T
    J Med Toxicol; 2016 Mar; 12(1):82-94. PubMed ID: 26586253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Addiction disorders of New Jersey physicians.
    Canavan DI
    N J Med; 1993 Nov; 90(11):861-2. PubMed ID: 8272281
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ["Addiction" to phenelzine - case report].
    Antosik-Wójcińska AZ; Bzinkowska D; Chojnacka M; Swiecicki Ł; Torbiński J
    Psychiatr Pol; 2013; 47(1):127-34. PubMed ID: 23888750
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review of addiction.
    Clay SW; Allen J; Parran T
    Postgrad Med; 2008 Jul; 120(2):E01-7. PubMed ID: 18654058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal clearance of gamma-hydroxybutyric acid in rats: increasing renal elimination as a detoxification strategy.
    Morris ME; Hu K; Wang Q
    J Pharmacol Exp Ther; 2005 Jun; 313(3):1194-202. PubMed ID: 15722403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility of D-glucuronate to enhance gamma-hydroxybutyric acid metabolism during gamma-hydroxybutyric acid toxicity: pharmacokinetic and pharmacodynamic studies.
    Bhattacharya I; Boje KM
    Biopharm Drug Dispos; 2007 Jan; 28(1):1-11. PubMed ID: 17061294
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outpatient versus inpatient opioid detoxification: a randomized controlled trial.
    Day E; Strang J
    J Subst Abuse Treat; 2011 Jan; 40(1):56-66. PubMed ID: 21036514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence.
    Galloway GP; Frederick SL; Staggers FE; Gonzales M; Stalcup SA; Smith DE
    Addiction; 1997 Jan; 92(1):89-96. PubMed ID: 9060200
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: five case studies.
    McDaniel CH; Miotto KA
    J Psychoactive Drugs; 2001; 33(2):143-9. PubMed ID: 11476261
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Current knowledge on gamma-hydroxybutyric acid (GHB), gamma-butyrolactone (GBL) and 1 ,4-butanediol (1,4-BD)].
    Dematteis M; Pennel L; Mallaret M
    Rev Prat; 2012 May; 62(5):669-72. PubMed ID: 22730800
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inpatient management of gamma-hydroxybutyrate withdrawal.
    Cappetta M; Murnion BP
    Australas Psychiatry; 2019 Jun; 27(3):284-287. PubMed ID: 30652947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.